Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653)

Market Cap	35.45B
Revenue (ttm)	3.67B
Net Income (ttm)	384.75M
Shares Out	1.10B
EPS (ttm)	0.35
PE Ratio	91.55
Forward PE	71.99
Dividend	0.29 (0.90%)
Ex-Dividend Date	May 24, 2024

Volume	2,023,820
Open	32.61
Previous Close	32.13
Day's Range	31.80 - 32.96
52-Week Range	18.59 - 34.07
Beta	0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2024

About Haisco Pharmaceutical Group

Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular. The company was formerly known as Xizang Haisco Pharmaceut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 5,448
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2023, Haisco Pharmaceutical Group's revenue was 3.36 billion, an increase of 11.27% compared to the previous year's 3.02 billion. Earnings were 295.11 million, an increase of 6.51%.